Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Thermo Fisher Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Thermo Fisher Scientific wird ein jährliches Gewinn- und Umsatzwachstum von 12% bzw. 5.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18% betragen.

Wichtige Informationen

10.6%

Wachstumsrate der Gewinne

11.3%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	5.6%
Zukünftige Eigenkapitalrendite	17.7%
Analystenabdeckung	Good
Zuletzt aktualisiert	04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Apr 27

Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results

Feb 02

Recent updates

Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends

Jun 07

Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)

Apr 30

Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Apr 27

Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching

Apr 24

Thermo Fisher Scientific: Too Hot To Handle

Apr 15

Investors Still Waiting For A Pull Back In Thermo Fisher Scientific Inc. (NYSE:TMO)

Apr 02

We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt

Mar 12

Thermo Fisher's Bright Future Makes It A Great Buy On Weakness

Feb 06

Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results

Feb 02

Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics

Jan 16

Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With 'Hold'

Jan 06

Is Now An Opportune Moment To Examine Thermo Fisher Scientific Inc. (NYSE:TMO)?

Dec 29

Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?

Dec 11

Thermo Fisher Scientific: I Am Still Waiting For An Attractive Buying Opportunity.

Dec 02

Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Could Be 25% Below Their Intrinsic Value Estimate

Nov 07

Gewinn- und Umsatzwachstumsprognosen

NYSE:TMO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	49,501	8,003	8,510	10,451	19
12/31/2025	46,112	6,915	7,850	9,351	25
12/31/2024	43,023	6,115	7,197	8,641	25
3/30/2024	42,492	6,034	7,560	8,928	N/A
12/31/2023	42,857	5,995	6,927	8,406	N/A
9/30/2023	43,421	5,941	6,546	8,170	N/A
7/1/2023	43,524	5,721	5,854	7,693	N/A
4/1/2023	43,807	6,024	5,620	7,681	N/A
12/31/2022	44,915	6,950	6,911	9,154	N/A
10/1/2022	44,167	7,032	5,600	8,124	N/A
7/2/2022	42,820	7,439	6,336	8,837	N/A
4/2/2022	41,123	7,603	7,001	9,536	N/A
12/31/2021	39,211	7,725	6,789	9,312	N/A
10/2/2021	39,059	8,565	7,916	10,194	N/A
7/3/2021	38,250	8,596	8,132	10,252	N/A
4/3/2021	35,894	7,924	8,062	9,911	N/A
12/31/2020	32,218	6,375	6,815	8,289	N/A
9/26/2020	28,497	4,879	5,686	6,863	N/A
6/27/2020	26,248	3,706	4,245	5,272	N/A
3/28/2020	25,647	3,669	3,702	4,680	N/A
12/31/2019	25,542	3,696	4,047	4,973	N/A
9/28/2019	25,220	3,592	3,940	4,861	N/A
6/29/2019	24,868	3,541	4,086	4,964	N/A
3/30/2019	24,630	3,174	4,273	5,114	N/A
12/31/2018	24,358	2,938	3,785	4,543	N/A
9/29/2018	23,898	2,570	3,919	4,608	N/A
6/30/2018	23,094	2,395	3,689	4,317	N/A
3/31/2018	22,006	2,256	3,189	3,722	N/A
12/31/2017	20,918	2,228	N/A	4,005	N/A
9/30/2017	19,824	2,330	N/A	3,344	N/A
7/1/2017	19,199	2,270	N/A	3,220	N/A
4/1/2017	18,744	2,174	N/A	3,284	N/A
12/31/2016	18,274	2,025	N/A	3,258	N/A
10/1/2016	17,973	1,999	N/A	3,281	N/A
7/2/2016	17,606	2,003	N/A	3,220	N/A
4/2/2016	17,341	1,998	N/A	3,072	N/A
12/31/2015	16,965	1,980	N/A	2,942	N/A
9/26/2015	16,806	1,978	N/A	2,543	N/A
6/27/2015	16,854	1,971	N/A	2,475	N/A
3/28/2015	16,905	1,738	N/A	2,598	N/A
12/31/2014	16,890	1,896	N/A	2,620	N/A
9/27/2014	15,864	1,635	N/A	2,394	N/A
6/28/2014	14,884	1,482	N/A	2,224	N/A
3/29/2014	13,802	1,481	N/A	1,814	N/A
12/31/2013	13,090	1,279	N/A	2,011	N/A
9/28/2013	12,883	1,322	N/A	1,942	N/A
6/29/2013	12,777	1,304	N/A	1,917	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TMODas prognostizierte Gewinnwachstum (12.3% pro Jahr) liegt über der Sparquote (2.3%).

Ertrag vs. Markt: TMODie Erträge des Unternehmens (12.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.6% pro Jahr).

Hohe Wachstumserträge: TMODie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: TMODie Einnahmen des Unternehmens (5.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.1% pro Jahr).

Hohe Wachstumseinnahmen: TMODie Einnahmen des Unternehmens (5.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: TMODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.4%).

Thermo Fisher Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Price target decreased by 7.4% to US$567

Recent updates

Upcoming dividend of US$0.39 per share

Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends

Chairman notifies of intention to sell stock

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

First quarter dividend of US$0.39 announced

Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

Senior VP & CFO notifies of intention to sell stock

Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)

Senior VP & General Counsel notifies of intention to sell stock

Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching

Thermo Fisher Scientific: Too Hot To Handle

Thermo Fisher Scientific Inc. Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Introduces Its Newest Line of High Performance, Ultra-Low Temperature (ULT) Freezers

Thermo Fisher Scientific Inc. to Report Q1, 2024 Results on Apr 24, 2024

Investors Still Waiting For A Pull Back In Thermo Fisher Scientific Inc. (NYSE:TMO)

Thermo Fisher Scientific Announces A New In-Line Metrology Solution to Improve Battery Safety and Performance

Chairman notifies of intention to sell stock

We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt

Thermo Fisher Scientific Inc. Launches Corevitas Clinical Registry in Generalized Pustular Psoriasis

Upcoming dividend of US$0.39 per share

Chairman notifies of intention to sell stock

Fourth quarter dividend increased to US$0.39

Thermo Fisher Scientific Inc. Increases Quarterly Cash Dividend, Payable on April 15, 2024

Chairman notifies of intention to sell stock

Thermo Fisher Scientific Inc. Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Senior VP & General Counsel notifies of intention to sell stock

Thermo Fisher's Bright Future Makes It A Great Buy On Weakness

Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Receives GMP Approval from the Italian Medicines Agency for its Manufacturing Facility of RNA-Based Products in Monza, Italy

Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics

Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With 'Hold'

Is Now An Opportune Moment To Examine Thermo Fisher Scientific Inc. (NYSE:TMO)?

Thermo Fisher Scientific Inc. Announces Launch of Innovative Corevitas Pharmacovigilance Platform for Clinical Research Registries

Thermo Fisher Scientific Inc. Announces the Launch of the Thermo Scientific KingFisher Apex Dx and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit

Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific: I Am Still Waiting For An Attractive Buying Opportunity.

Thermo Fisher Scientific Declares Quarterly Dividend, Payable on January 16, 202

Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Could Be 25% Below Their Intrinsic Value Estimate

Chairman notifies of intention to sell stock

Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors

My Family Is Buying A Lot More Thermo Fisher Stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Price target decreased by 7.4% to US$567

Now 24% undervalued after recent price drop

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. to Report Q3, 2023 Results on Oct 25, 2023

Thermo Fisher: An Up To 35% Undervalued Healthcare Gem I Like On Weakness

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?

Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with A Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™

Upcoming dividend of US$0.35 per share at 0.3% yield

Executive Vice President notifies of intention to sell stock

Thermo Fisher Scientific: A High-Quality Investment For Double-Digit Returns

Thermo Fisher Scientific Announces the Launch of the EXENT Solution with IVDR Certification

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Thermo Fisher Scientific Inc. (NYSE:TMO) acquired CorEvitas, LLC from Audax Management Company, LLC for approximately $910 million.